Meeting
2019 Genitourinary Cancers Symposium
Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Daniel J. George
Duke Cancer Institute, Durham, NC
Daniel J. George , Cora N. Sternberg , A. Oliver Sartor , Fred Saad , Bertrand F. TOMBAL , Kurt Miller , Jan Kalinovsky , XiaoLong Jiao , Krishna Tangirala , Celestia S. Higano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 253)
DOI
10.1200/JCO.2019.37.7_suppl.253
Abstract #
253
Poster Bd #
L10
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neal D. Shore
Poster
2021 Genitourinary Cancers Symposium
Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.
First Author: Oliver A. Sartor
Poster
2020 Genitourinary Cancers Symposium
Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).
First Author: Daniel J. George
Poster
2020 Genitourinary Cancers Symposium
Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neal D. Shore